Viking Therapeutics Inc
Suletud
SektorTervishoid
31.38 -1.69
Ülevaade
Aktsiahinna muutus
24h
Min
31.78
Max
32.08
Sissetulek | 30M -128M |
|---|---|
Aktsiakasum | -1.1 |
Töötajad | 65 |
EBITDA | 30M -128M |
Järgmine tulemuste avaldamine | 21. okt 2026 |
|---|
Turukapital | 19M 4.1B |
|---|---|
Eelmine avamishind | 33.07 |
Eelmine sulgemishind | 31.38 |
Uudiste sentiment
By Acuity
50%
50%
126 / 339 Pingereas Healthcare
Viking Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Viking Therapeutics Inc Prognoos
Sentiment
By Acuity
126 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.